Abstract:e12656 Background: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer, constituting approximately 15-20% of all breast cancer cases. While less than 10% of all breast cancer patients harbor BRCA1/2 mutations, ~20% of TNBC patients carry these mutations. Notably, at least one-third of BRCA1 carriers develop TNBC. This study aimed to investigate the association between BRCA mutation status and pathological response (PR) in early-stage TNBC patients, specifically, the impact of BRCA positivity on achieving pathological complete response (pCR), and identify other potential predictors of PR. Methods: We conducted a retrospective cohort study of patients with early-stage (Stage I-III) triple-negative breast cancer diagnosed and treated at our institution between January 2012 and June 2022, following Institutional Review Board (IRB) approval. Patients were identified from our Institutional Cancer Registry based on complete data availability (including other inclusion criteria) excluding patients who did not receive neoadjuvant chemotherapy. Data on demographics, tumor characteristics, treatment regimens, and pathological response (assessed according to [specified criteria]) were extracted from the charts. Results: Out of 228 patients diagnosed with early-stage triple-negative breast cancer, 54.6% had no genetic mutations, while 7.9%, 4.9%, and 8.4% harbored BRCA1, BRCA2, and other mutations, respectively. Notably, 23.4% did not receive genetic counseling or testing at our institution. Patients with BRCA2 mutations had a 100% pathological response rate, of which 57.14% had pCR, compared to 85.7% for BRCA1, of which 71.43% had pCR. Furthermore, 93.8% of patients with other genetic mutations had pathological response, of which 56.25% had pCR, as compared to 68.42% in non-mutated cases of which 26.7% had pCR ( P=0.038). Analysis of other variables revealed no significant impact of age, BMI, performance status, or neoadjuvant chemotherapy regimen on pathological response. Conclusions: This retrospective study suggests a trend towards higher complete pathological responses in early-stage triple-negative breast cancer patients with BRCA and other genetic mutations compared to those without. These findings were statistically significant, indicating a potential clinical trend that specific genetic mutations may be associated with improved response to neoadjuvant chemotherapy in early-stage triple-negative breast cancer. Further research is needed to confirm these findings and guide the development of personalized treatment strategies based on a patient's genetic profile. Additionally, our findings highlight the importance of genetic testing for all patients with early-stage triple-negative breast cancer, regardless of age or family history.

Prevalence of BRCA 1 mutations and responses to neoadjuvant chemotherapy among BRCA 1 carriers and non-carriers with triple-negative breast cancer

Prevalence of Brca1 Mutations and Responses to Neoadjuvant Chemotherapy among Brca1 Carriers and Non-Carriers with Triple-Negative Breast Cancer

Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.

[Relationship of Clinicopathological Features and Chemotherapeutic Outcomes in Women with BRCA1 and BRCA2 Mutation-Negative Familial Breast Cancer].

Predictive Value of BRCA1/2 Mrna Expression for Response to Neoadjuvant Chemotherapy in BRCA‐negative Breast Cancers

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers

Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer

Prevalence and Characterization of BRCA1 and BRCA2 Germline Mutations in Chinese Women with Familial Breast Cancer

Impact of the addition of carboplatin to anthracycline‐taxane‐based neoadjuvant chemotherapy on survival in <i>BRCA1/2</i> ‐mutated triple‐negative breast cancer

Predicting pathological response in early-stage triple-negative breast cancer: Exploring the role of BRCA gene mutations—A retrospective single-institution study.

Impact of the Addition of Carboplatin to Anthracycline-Taxane-based Neoadjuvant Chemotherapy on Survival in BRCA1/2-mutated Triple-Negative Breast Cancer.

Efficacy of Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer and Prognostic Analysis

Germline and Tumor BRCA1/2 Pathogenic Variants in Chinese Triple-Negative Breast Carcinomas

Prognostic and Predictive Markers for Early Stage Triple‐Negative Breast Cancer Treated With Platinum‐Based Neoadjuvant Chemotherapy

Breast-conserving Therapy is Safe Both Within BRCA1/2 Mutation Carriers and Noncarriers with Breast Cancer in the Chinese Population

Association Between CHEK2 H371Y Mutation and Response to Neoadjuvant Chemotherapy in Women with Breast Cancer

Brca1 Germline Mutations and Tumor Characteristics in Chinese Women with Familial or Early-Onset Breast Cancer

Insights into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer

BRCA Mutation Frequency and Clinical Features of Ovarian Cancer Patients: A Report from a Chinese Study Group

Prevalence Of Brca1 And Brca2 Gene Mutations In Chinese Patients With High-Risk Breast Cancer